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Background: The impact of thoracic three-dimensional radiotherapy on the prognosis for stage IV non-small-cell
lung cancer is unclear. This study is to investigate survival outcomes and prognosis in patients with stage IV non-small
cell lung cancer (NSCLC) treated with thoracic three-dimensional radiotherapy and systemic chemotherapy.
Methods: Ninety three patients with stage IV NSCLC had received at least four cycles of chemotherapy and thoracic
three-dimensional radiotherapy of ≥40 Gy on primary tumors. The data from these patients were retrospectively
analyzed.
Results: Of the 93 patients, the median survival time (MST) was 14.0 months, and the 1, 2, and 3-year survival rates
were 54.8%, 20.4%, and 12.9%, respectively. The MST of patients received radiation dose to primary tumor ≥63Gy and
<63 Gy for primary tumor were 15.0 and 8.0 months, respectively (P = 0.001). Patients had metastasis to a single site
and lower tumor volume (<170 cm3) also produced longer overall survival time (P = 0.002, P = 0.020, respectively). For
patients with metastasis at a single site, thoracic radiation dose ≥63 Gy remained a prognostic factor for better overall
survival (P = 0.030); patients with metastases at multiple sites, radiation dose ≥63 Gy had a trend to improve overall
survival (P = 0.062). A multivariate analysis showed that radiation dose ≥63 Gy (P = 0.017) and metastasis to a single site
(P = 0.038) are associated with better overall survival, and the volume of primary tumor was marginally correlated with
OS (P = 0.054).
Conclusions: In combination with systemic chemotherapy, radiation dose ≥63 Gy on primary tumor and metastasis to
a single site are significant factors for better OS, aggressive thoracic radiotherapy may have an important role in
improving OS.
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Approximately 55% of patients who have been newly
diagnosed with non-small-cell lung cancer (NSCLC) have
distant metastases [1]. For NSCLC patients with stage IV
disease and good performance status, platinum-based
combination therapy improves survival and quality of life,* Correspondence: lbgymaaaa@sohu.com
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[2]. Thoracic radiotherapy is often used as a palliative
treatment for patients with stage IV NSCLC to relieve
symptoms (i.e. hemoptysis, cough, chest pain, dyspnea,
etc.) that are caused by locoregional growth of primary
tumor [3,4].
Recent publications have reported that radiotherapy of
the primary tumor may prolong the survival time of
patients with NSCLC involving limited metastatic lesions,
and radiation dose to primary thoracic tumor were associ-
ated with survival time [5,6]. Higginson et al. [7] conductedis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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or stage IV, who had never received radiotherapy, from
nine prospective clinical studies, and revealed that in-
trathoracic disease burden had prognostic significance,
patients with bulky central disease, bronchial/vascular
compression, and/or pulmonary symptoms had worse
overall survival after first-line, platinum-based chemo-
therapy. These results suggest that patients with stage IV
disease may benefit from thoracic radiation. Chemo-
therapy is the main treatment for stage IV NSCLC. However,
the research on thoracic three dimensional radiotherapy with
chemotherapy for stage IV NSCLC has been limited, and
more studies are needed to confirm the outcomes of this
treatment modality [8,9]. Therefore, we retrospectively
analyze the survival outcomes and prognostic factors in
stage IV NSCLC patients who received at least four cycles
of chemotherapy and at least 40 Gy of thoracic radiation
to primary tumor.
Methods
Patient selection and pretreatment evaluation
Ninety-three patients with stage IV NSCLC and fulfilled
all of the following criteria have been included in this
study. The inclusion criteria were as follows: (1) patho-
logically or cytologically confirmed diagnosis of NSCLC;
(2) newly diagnosed stage IV disease according to the
staging system of the 2002 American Joint Committee
on Cancer (AJCC); (3) age between 18 and 80 years; (4)
Karnofsky Performance Status (KPS) score ≥ 70, as well
as a weight loss of no more than 10% during the six
months prior to therapy; (5) patients had adequate bone
marrow function, liver function and renal function; (6)
no radiotherapy or chemotherapy contraindications; (7)
the primary thoracic tumor received radiation of at
least 40 Gy; (8) thoracic radiation using either three-
dimensional conformal radiation therapy (3D-CRT) or
intensity-modulated radiation therapy (IMRT); (9) treat-
ment with at least four cycles of systemic chemotherapy;
and (10) limited metastatic disease (≤5 sites). The exclu-
sion criteria were as follows: (1) history of thoracic
operation, radiotherapy or chemotherapy; (2) pregnancy
or lactation; (3) previous malignancy or other concomitant
malignant disease. The Institutional Review Board of the
Affiliated Hospital of Guiyang Medical College and
Guizhou Cancer Hospital China approved this study,
and the informed consent was obtained from all patients.
Pretreatment evaluation included a complete physical
examination, hematologic and biochemistry profiles.
Fiberoptic bronchoscopic examination and contrast-
enhanced computed tomography (CT) of chest were
performed to accurately evaluate the extent of the pri-
mary tumor and regional lymph nodes. Bone scan,
contrast-enhanced CT of the abdominal region, and
magnetic resonance imaging of head were routinelyused to detect distant metastases. Additional investigations
were performed if indicated.
Radiotherapy protocol
All patients were immobilized in the supine position
with a T bar, wing board, and Vac-lock cradle. Images with
contrast were obtained from the computed tomography
simulator for treatment planning purpose. All patients
were scanned with serial 5-mm slices from the hyoid
bone through the third lumbar vertebra. IMRT or 3D-
CRT treatment plans was designed for patients using
the ADAC pinnacle3 planning system (version 7.4f ) and
dose distribution was computed with tissue heterogeneity
correction. The gross tumor volume (GTV) included
thoracic primary tumours and hilar or mediastinal lymph
nodes with a short-axis diameter of at least 1 cm on CT,
and the planning target volume (PTV) was defined as the
GTV plus a 1.5-cm margin for setup uncertainty and
respiratory motion. Radiation was delivered with a linear
accelerator using 6 MV photons. V20 (percentage of the
total lung volume receiving ≥20 Gy), the maximal point
dose of spinal cord and mean esophagus dose was re-
quired ≤32%, 50 Gy and ≤35 Gy, respectively, for in-
dividual treatment plan. Patients received late-course
accelerated hyperfractionated radiotherapy (LCAHRT)
to thoracic primary site with 3D-CRT or IMRT tech-
niques. The first course of radiation given in 2 Gy per
fraction, 5 days a week for a dose of 40 Gy, LCAHRT was
delivered in 2 fractions of 1.5 Gy with an interval of 6–8 h
per day. A radiation prescription dose of 60–70 Gy were
decided to give to patients; if individual tolerability is not
acceptable, lower doses of at least 40 Gy should be given.
The PTV should be covered by at least the 90% isodose
surface. Under the acceptable radiation dose to the normal
tissue, radiation dose to thoracic primary tumor can be
escalated to 74Gy. Thoracic radiation treatment was
implemented concurrently with chemotherapy. All pa-
tients received thoracic radiation at least a dose of
40 Gy in 20 fractions (5 days each week). The fraction-
ated radiotherapy dose for the metastatic tumors
ranged from 3–10 Gy/fraction with 1 fraction/day, and
the total prescribed radiotherapy dose for metastatic
lesions ranged from 20–60 Gy. Concurrent thoracic
radiation to primary tumor was given within one week
following the start of chemotherapy, and radiation to
metastatic lesions was implemented concurrently or
sequentially with chemotherapy.
Chemotherapy protocol
Platinum-based doublets chemotherapy was used for all
patients, the selection of regimens was according to
prior studies [10,11]. The commonly used regimens and
usage are as following: 135 mg-175 mg of paclitaxel (P) per
square meter of body-surface area (mg/m2) or 75 mg/m2 of














































Table 1 Clinical characteristics (93 cases) (Continued)











Su et al. Radiation Oncology  (2014) 9:290 Page 3 of 7docetaxel (D) on day 1, followed by 80 mg/m2 of cisplati-
num (C) or carboplatin (Cb) at a dose of 300 mg/m2-
350 mg/m2 were administrated on day 2, and vinorelbine
(V) at a dose of 25 mg/m2 was administered on days 1
and 8 during thoracic radiotherapy every 21–28 days.
After completion of thoracic radiotherapy, patients dem-
onstrating a response or stable disease continued chemo-
therapy up to four to six cycles, whereas patients who
experienced progressive disease or unacceptable toxicity
were transferred to second-line therapy. Platinum and
taxane-based were main regimens used in current study,
PC or PCb regimens were utilized in 38 cases; DC
regimens in 51 cases, VC regimen in 4 cases. In total,
89 patients received four cycles of chemotherapy, and
4 patients received five cycles of chemotherapy.
Statistical analysis
The Statistical Package for Social Sciences, version 13.0
(SPSS, Chicago, IL) was used for statistical analysis. The
Kaplan-Meier method was used to calculate the overall
survival. The log–rank test was used to compare the
survival curves. Multivariate cox regression analyses was
used to test independent significant prognostic factors
for OS. All statistical tests were two-sided, and p < .05
was considered statistically significant.
Results
Survival analysis
Totally, 93 patients were included in this study, the
clinical characteristics of the 93 patients are detailed in
Table 1. The male/female ratio was nearly 2.6:1.0 and
the patient age range were 28 to 78 years (median, 57).
The T and N stages were as follows: 32 cases T1−2,
61 T3−4, and 15 N0−1 and 78 N2-3. Fifty-six (60.2%) pa-
tients had metastasis in only one site, 37 (39.8%) patients
in ≥2 sites. The most common site of metastatic disease at
diagnosis was the bone (55.9% of patients), 34 (36.6%)
patients had lung metastasis, and 23 (25.8%) patients had
metastasis in brain.
Figure 1 Comparison of overall survival curves at different radiation dose.
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with a median follow-up period of 14.0 months. By the
last follow-up, 88 patients was dead, whereas five patients
remained alive, the survival times of these five patients
was 34.0-80.0 months, with a median survival time (MST)
of 64.0 months. For all patients, MST was 14.0 months
(95% confidence interval (CI), 11.44-16.60), the 1-year,
2-year, and 3-year survival rates were 54.8%, 20.4%, and
12.9%, respectively. Among 61 of the patients who died,Figure 2 Comparison of overall survival curves between a single sitethe patterns of tumor recurrence and persistence were
evaluated: two cases had progressive disease in primary
tumor without developing any new metastases, 3 cases
had progressive disease in primary tumor with new me-
tastases, 4 cases had progressive disease in primary
tumor and initially metastatic lesions, 48 cases had new
metastases in initially involved or uninvolved organs,
and 4 cases had no tumor progression (including three
patients who died of lung infections and one patientmetastases and multi-site metastases.
Table 2 Univariate analysis for overall survival
Varable No. 1-year 2-year 3-year P value
Gender
Male 67 53.7 25.4 11.9 0.833
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only 3 patients received treatment of epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors (TKI);
the overall survival time of these 3 patients was 26.0,
27.0, and 44.0 months, respectively.Female 26 57.7 19.2 15.4
Age (years)
<60 56 51.8 16.1 8.9 0.152
≥60 37 59.5 27.0 18.9
KPS
≤80 64 50.0 17.2 7.8 0.055
>80 29 58.6 27.6 24.1
Pathological type
Non-Squamous 27 55.9 17.7 7.7 0.160
Squamous 66 47.3 10.9 10.9
GTV (cm3)
<170 45 66.7 31.1 20.0 0.020
≥170 48 43.8 10.4 6.2
T stage
T1-2 32 59.4 25.0 18.8 0.339
T3-4 61 52.5 18.0 9.8
N stage
N0-1 15 66.7 33.3 26.7 0.229
N2-3 78 52.6 19.2 10.3
Metastatic status
Single site 56 62.5 26.8 19.6 0.002
Multiple sites 37 43.2 10.8 2.7
Thoracic radiation dose
<63Gy 29 31.0 10.3 3.4 0.001
≥63Gy 64 65.6 25.0 17.2
Response of primary tumor
CR 5 80.0 40.0 20.0 0.000
PR 66 59.1 21.2 12.1
NC 18 44.4 16.7 16.7Prognostic factors analysis
Univariate analysis showed that receipt of at least 63 Gy
to the primary tumor (Figure 1), metastasis to a single site
(Figure 2), GTV <170 cm3, and had response of primary
tumor were significantly associated with better OS; and
KPS score > 80 was marginally with better OS (P = 0.055).
Table 2 showed univariate analysis of various potential
prognostic factors on predicting OS.
According to GTV size, for patients with tumor vol-
ume ≥170 cm3, the MST was 14.0 months (95% CI,
12.7–15.3) for those received radiation ≥63 Gy, and the
MST was 8.0 months (95% CI, 5.9-10.1) for those received
radiation <63Gy (χ2 = 5.609, P = 0.018); for patients with
tumor volume < 170 cm3, radiation dose ≥ 63 Gy had a
trend towards a better OS (χ2 = 2.376, P = 0.123). We then
subdivided the whole group into patients with metastasis
at a single site and multiple sites. For patients with me-
tastasis to a single sites, the MST was 16.0 months (95%
CI, 12.45-19.55) for patients who received radiation
dose ≥63 Gy, and 10.0 months (95% CI, 8.33-11.67) for
patients who received radiation dose < 63 Gy (χ2 = 4.733,
P = 0.030). For patients with metastasis to multiple sites,
patients who received ≥ 63 Gy had a MST of 14.0 months
(95% CI, 9.99-18.01), whereas the patients who re-
ceived <63 Gy had a MST of 7.0 months (95% CI,
6.01-7.99) (χ2 = 3.488, P = 0.062). Patients with and with-
out brain metastasis had similar OS (χ2 = 2.502, P = 0.114).
The multivariate analysis showed that the number of
metastatic sites, and radiation dose of the primary thoracic
tumor were independent prognostic factors for OS, and
the volume of primary tumor was marginally correlated
with OS (Table 3).PD 4 0 0 0
Radiation to metastases
Yes 50 58.9 22.0 14.0 0.759
No 43 51.2 18.6 11.6Discussion
The response rate for platinum-based doublet chemo-
therapy for stage IV NSCLC is approximately 30%-40%,
and this treatment produces a MST of 8.0-10.0 months.
Different third-generation chemotherapy regimens have
similar efficacies, indicating that the efficacy of a chemo-
therapeutic approach has reached a plateau [11,12]. This
study sought to investigate whether combining systemic
chemotherapy with radiotherapy of the primary thoracic
tumor could further improve survival. Compared with
historical data [11,12], the survival time of patients
treated with this combined therapy in current study
were increased. The multivariate analysis demonstrated
that radiation ≥63 Gy for the primary thoracic tumorand metastasis to only a single site are independent
prognostic factors for better survival.
Systemic chemotherapy is the primary treatment for
stage IV NSCLC, and four to six cycles of chemotherapy
is recommended [2]. Radiotherapy can effectively amelior-
ate the various symptoms caused by the primary tumor,
including hemoptysis, pain, coughing, and dyspnea;
however, patients often only receive palliative dose of
radiotherapy [9,13,14]. The current study revealed that
Table 3 Multivariate analysis for overall survival
Variable HR 95.0% confidence interval P
valueLower Upper
Sex (female vs. male) 1.265 0.701 2.284 0.435
Age (<60 y vs. ≥ 60y) 0.953 0.552 1.646 0.864
Karnofsky performance status (≤80 vs. >80) 0.779 0.425 1.428 0.420
Pathological type (Squamous vs.Non-Squamous ) 1.314 0.785 2.199 0.298
Tumor volume (per cm3 incerase) 1.002 1.000 1.003 0.054
T stage (T3-4 vs.T1-2) 1.209 0.677 2.157 0.521
N stage (N2-3 vs.N0-1) 1.015 0.435 2.366 0.973
Metastasis status (multi- vs. single) 1.765 1.032 3.018 0.038
Thoracic radiation dose (≥63 Gy vs. <63 Gy) 0.547 0.333 0.897 0.017
Response of primary tumor (SD + PD vs. CR + PR) 1.232 0.574 2.642 0.592
Radiotherapy to metastases (yes vs. no) 0.890 0.511 1.551 0.681
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diation ≥63 Gy to the primary thoracic tumor was
15.0 months, which is significantly higher than the
MST of 8.0 months among the patients received a
dose <63 Gy. A multivariate analysis indicated that a
dose ≥ 63 Gy is an independent prognostic factor for
survival, demonstrating that treatment with a radical
dose of radiotherapy to the primary tumor can prolong
the survival time of patients with stage IV NSCLC. Nearly
50% of stage IV NSCLC patients develop local recurrence
in initially involved sites, local control and status of
primary tumor was associated with OS [7,15,16]. These
findings suggest that local control of the primary
tumor plays an important role in prolonging the sur-
vival of patients with stage IV NSCLC.
Consistent with Lopez et al. [6], our result also showed
that patients with a lower tumor volume had better
outcomes. In subgroup analysis, among patients with
larger tumors (GTV > 170 cm3) or metastasis to only a
single site, we found that patients who received ≥63 Gy
had a significantly improved OS than those who re-
ceived < 63 Gy. Our findings suggest that primary tumor
volume and metastasis status may be used as a criterion
for selecting patients for aggressive radiation therapy in
this setting.
In the current study, an analysis of the outcomes for
61 patients with confirmed causes of death revealed that
57 patients died of tumor progression, 48 patients died
of new metastases, 7 patients died due to local recur-
rences accompanied by distant metastases, and only 2
patients died of local recurrences alone. These results
demonstrate that aggressive radiotherapy can reduce the
risk of death from local recurrence. Moreover, the inves-
tigation of more effective systemic treatment regimens is
important for improving the prognosis of stage IV
NSCLC. Lopez et al. [6] found that the radiation doseof the primary thoracic tumor was associated with sur-
vival among patients with stage IV NSCLC, suggesting
that the administration of aggressive radiotherapy to
the primary tumor can improve survival. Arrieta et al.
[5] reported that in NSCLC patients with metastases
only in the brain, if the absence of progression was
assessed after receiving two cycles of systemic chemo-
therapy and received radiation of the metastatic lesions
in the brain, the survival outcomes could be improved
by the administration of active concurrent chemora-
diotherapy of the patients’ thoracic primary tumors; in
particular, this therapeutic approach achieved an MST
of 31.8 ± 15.8 months.
Hellman et al. [17] proposed a notion is that of oligome-
tastases in 1995, oligometastases is the state in which the
patient shows distant relapse in only a limited number of
regions. In the current study, a multivariate analysis indi-
cated that metastasis to only a single site was an inde-
pendent prognostic factor for survival. The subgroup
analysis demonstrated that radiotherapy with a high dose
radiation (≥63 Gy) to primary thoracic tumor may not
only provide survival benefits to patients with metastasis
to a single site but also have a trend to improve the
survival for patients with metastases in multiple sites.
The current study data suggest that NSCLC patients
with limited metastatic disease could derive a greater
benefit from radiotherapy for their primary tumors.
Several retrospective studies have also showed that pa-
tients with imited stage IV NSCLC can benefit from
aggressive radiotherapy of primary tumors [5,6,18].
Mehta et al. [16] reported that 74% of stage IV NSCLC
patients had metastases confined to one or two sites
and 50% had ≤3 metastatic sites at initial diagnosis,
and 50% had stable or progressive disease in initially
involved sites without developing any new metastatic
tumors at last follow-up. These data suggest that a
Su et al. Radiation Oncology  (2014) 9:290 Page 7 of 7subset of patients who present with metastatic NSCLC
may not have widely disseminated disease, and local
treatment combined with systemic therapy might be
beneficial in these patients.
Conclusions
In summary, newly diagnosed NSCLC patients with
metastasis may benefit from aggressive radiotherapy
(of ≥63 Gy) to primary thoracic tumor based on sys-
temic chemotherapy. Patients with metastasis to only a
single site and smaller tumor volume tend to benefit
most from this aggressive treatment modality, although
this approach also have a trend to provide survival
benefits for patients with metastases in multiple sites.
The administration of aggressive radiotherapy to control
primary tumors may play an important role in improving
survival of NSCLC patients with metastases. Because of
the retrospective nature of current study, a randomized
trial is necessary to evaluate the causal effect of radiation
dose on OS.
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